Evidence map›Paper›PMID 32792624›Full record

ArticleEuropean journal of human genetics : EJHG2020

Reply to Kratz et al.

Thierry Frebourg, Svetlana Bajalica Lagercrantz, Carla Oliveira, Rita Magenheim, D Gareth Evans, European Reference Network GENTURIS

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of human genetics : EJHG, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. GermlineCancers · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Thierry FrebourgDepartment of Genetics, Rouen University Hospital and Inserm U1245, Normandy Centre for Genomic and Personalized Medicine, Normandie University, UNIROUEN, Rouen, France. frebourg@chu-rouen.fr.ORCID http://orcid.org/0000-0003-0399-4007
Svetlana Bajalica LagercrantzHereditary Cancer Unit, Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-7175-7102
Carla Oliveirai3S-Instituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, and Porto Comprehensive Cancer Center, Porto, Portugal.
Rita MagenheimCommunity Representative, Berlin, Germany.
D Gareth EvansDivision of Evolution and Genomic Sciences, Manchester Centre for Genomic Medicine, University of Manchester, MAHSC, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.ORCID http://orcid.org/0000-0002-8482-5784
European Reference Network GENTURIS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Neoplastic Syndromes, HereditaryHumansTumor Suppressor Protein p53TP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID32792624
PMCPMC7576774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.